Pyxis Oncology Inc (PYXS) FinancialsPYXSPyxis Oncology Inc

Evaluating the bottom line, Pyxis Oncology Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -179.10%, provide a clear picture of how effectively PYXS converts its operational activities into shareholder value.

In the context of the broader market, PYXS competes directly with industry leaders such as ACIU and MGNX. With a market capitalization of $312.78M, it holds a leading position in the sector. When comparing efficiency, PYXS's gross margin of N/A stands against ACIU's 100.00% and MGNX's N/A. Such benchmarking helps identify whether Pyxis Oncology Inc is trading at a premium or discount relative to its financial performance.

The company has reported zero revenue in the last three quarters but showed a gross profit of $8,650,000 in Q4 2025, indicating potential for future earnings as it develops its drug pipeline.